Braeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint.
Risperidone, the most commonly-prescribed therapy for schizophrenia, depends on consistent administration, but patients with schizophrenia sometimes stop taking their medication when their symptoms improve. Long-acting, injectable formulations of risperidone are on the market, but there is no FDA-approved formulation that lasts for 6-months, according to Braeburn.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial appeared first on MassDevice.